Literature DB >> 3486228

Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of Haemophilus influenzae.

G A Weinberg, D M Granoff, M H Nahm, P G Shackelford.   

Abstract

The biologic activity of different human IgG subclass antibodies directed against the Haemophilus influenzae type b (Hib) capsular polysaccharide (PRP) was compared by using an in vitro complement-mediated bactericidal assay and an in vivo passive protection assay in infant rats. An IgG pool was made by Sephacryl S-300 chromatography of sera from adults immunized with PRP vaccine. An IgG2 subclass fraction was prepared by column immunoabsorption of the IgG pool with anti-IgG1 monoclonal antibody. An IgG1 subclass fraction was eluted from the affinity matrix. IgG1, IgG2, IgG3, and IgG4 concentrations in the fractions were measured by solid-phase competitive radioimmunoassays, and anti-PRP antibody was measured by a modified Farr assay. Each fraction was greater than 90% pure IgG2 or IgG1, respectively. There were no significant differences in the minimal anti-PRP antibody concentrations required to kill 50% of Hib cells in vitro (IgG, 0.22; IgG1, 0.21; and IgG2, 0.42 microgram/ml). Similarly, equivalent amounts of anti-PRP antibody of the IgG1 or IgG2 fractions protected against bacteremia (IgG1, 0.12; IgG2, 0.24 microgram per rat). IgG absorbed to remove anti-PRP antibody was neither bactericidal nor protective. Thus IgG1 and IgG2 anti-PRP antibody have equivalent functional activities against Hib as determined by these biologic assays.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486228

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Phosphorylcholine antibodies in pulmonary infection.

Authors:  S Nishinarita; S Sawada; T Horie
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

2.  Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SF.

Authors:  A Soininen; I Seppälä; T Wuorimaa; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

3.  IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

Review 4.  Selective IgG subclass deficiency: quantification and clinical relevance.

Authors:  R Jefferis; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

5.  An association between homozygous C3 deficiency and low levels of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  M A Hazlewood; D S Kumararatne; A D Webster; M Goodall; P Bird; M Daha
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction.

Authors:  V Hammarström; K Pauksen; J Azinge; G Oberg; P Ljungman
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

7.  Comparison of naturally acquired and vaccine-induced antibodies to Haemophilus influenzae type b capsular polysaccharide.

Authors:  M T Jelonek; S J Chang; C Y Chiu; M K Park; M H Nahm; J I Ward
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

8.  Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

Authors:  R G Bredius; P C Driedijk; M F Schouten; R S Weening; T A Out
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  Prospective, randomized comparison of OM-85 BV and a prophylactic antibiotic in children with recurrent infections and immunoglobulin A and/or G subclass deficiency.

Authors:  Ferah Genel; Necil Kutukculer
Journal:  Curr Ther Res Clin Exp       Date:  2003-09

10.  Portrait: coincidences, convergences and opportunities.

Authors:  Dan M Granoff
Journal:  Hum Vaccin Immunother       Date:  2013-08-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.